<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35610313</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-1741</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Nature reviews. Immunology</Title><ISOAbbreviation>Nat Rev Immunol</ISOAbbreviation></Journal><ArticleTitle>Cardiometabolic syndrome - an emergent feature of Long COVID?</ArticleTitle><Pagination><StartPage>399</StartPage><EndPage>400</EndPage><MedlinePgn>399-400</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41577-022-00739-8</ELocationID><Abstract><AbstractText>Large-scale clinical studies on the post-infectious impacts of SARS-CoV-2 have suggested that patients who have recovered from acute infection have increased risk for cardiometabolic syndrome-associated morbidities such as diabetes, chronic kidney disease and heart failure. Initial studies have taken the first steps towards unravelling the molecular processes that may be driving these findings, including the role of immune and inflammatory factors, but a comprehensive aetiology remains unclear. Given that cardiometabolic syndrome progression in patients with Long COVID may pose a significant global health and economic burden post pandemic, there is an emergent need to identify therapeutic targets and treatment options.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frere</LastName><ForeName>Justin J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, New York University, Langone Health, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>tenOever</LastName><ForeName>Benjamin R</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0003-0324-3078</Identifier><AffiliationInfo><Affiliation>Department of Microbiology, New York University, Langone Health, New York, NY, USA. Benjamin.tenOever@nyulangone.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Immunol</MedlineTA><NlmUniqueID>101124169</NlmUniqueID><ISSNLinking>1474-1733</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024821" MajorTopicYN="Y">Metabolic Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="eng"><AbstractText>Among the multi-organ complications of Long COVID, those associated with cardiometabolic syndrome were some of the most prevalent in recent studies of population-scale data. Given the potential health and economic burdens, there is an urgent need to better define the inflammatory processes involved.</AbstractText></OtherAbstract><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>24</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35610313</ArticleId><ArticleId IdType="pmc">PMC9127811</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00739-8</ArticleId><ArticleId IdType="pii">10.1038/s41577-022-00739-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat. Immunol. 2022;23:194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 2022;10:311&#x2013;321. doi: 10.1016/S2213-8587(22)00044-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(22)00044-4</ArticleId><ArticleId IdType="pmc">PMC8937253</ArticleId><ArticleId IdType="pubmed">35325624</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022;28:583&#x2013;590. doi: 10.1038/s41591-022-01689-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Xu E, Al-Aly Z. Kidney outcomes in long COVID. J. Am. Soc. Nephrol. 2021;32:2851&#x2013;2862. doi: 10.1681/ASN.2021060734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021060734</ArticleId><ArticleId IdType="pmc">PMC8806085</ArticleId><ArticleId IdType="pubmed">34470828</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro JP, El-Atat FA, Mcfarlane SI, Aneja A, Sowers JR. Cardiometabolic syndrome: pathophysiology and treatment. Curr. Hypertens. Rep. 2003;5:393&#x2013;401. doi: 10.1007/s11906-003-0085-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-003-0085-y</ArticleId><ArticleId IdType="pubmed">12948432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoagland D, et al. Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity. 2021;54:557&#x2013;570. doi: 10.1016/j.immuni.2021.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.01.017</ArticleId><ArticleId IdType="pmc">PMC7846242</ArticleId><ArticleId IdType="pubmed">33577760</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang X, et al. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab. 2021;33:1577&#x2013;1591. doi: 10.1016/j.cmet.2021.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.05.015</ArticleId><ArticleId IdType="pmc">PMC8133495</ArticleId><ArticleId IdType="pubmed">34081913</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiterer M, et al. Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab. 2021;33:2174&#x2013;2188. doi: 10.1016/j.cmet.2021.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.09.009</ArticleId><ArticleId IdType="pmc">PMC8443335</ArticleId><ArticleId IdType="pubmed">34599884</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, et al. Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secreting CCL2. Stem Cell Rep. 2021;16:2274&#x2013;2288. doi: 10.1016/j.stemcr.2021.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.07.012</ArticleId><ArticleId IdType="pmc">PMC8289700</ArticleId><ArticleId IdType="pubmed">34403650</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>